Provision of Assay Kits for SCID & SMA In-Service Evaluations - EONIS-Q Revvity
EONIS-Q Assay methodology, as part of the delivery and implementation of the ongoing NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) in 4 Screening laboratories, with the addition of the ISE for Spinal Muscular Atrophy (SMA).
Buyer
NHS England
Value
£4,074,117
Published
12 Mar 2026
Closes
12 Mar 2026
Procurement details
Source
Contracts Finder
Region
London
Procurement method
Selective
Category
Goods
Contract starts
31 Mar 2026
Contract ends
31 Mar 2029
CPV classifications
33100000
Medical equipments
Lots
Lot default Provision of Assay Kits for SCID & SMA In-Service Evaluations - EONIS-Q Revvity
£4,074,117
EONIS-Q Assay methodology, as part of the delivery and implementation of the ongoing NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) in 4 Screening laboratories, with the addition of the ISE for Spinal Muscular Atrophy (SMA).
Delivery: United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
12 Mar 2026
Awarded contract notice on Contracts Finder
Award notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.